Background Care of patients with CKD requires expertise in advance care planning (ACP), including attention to ethical, psychosocial, and spiritual issues related to starting, continuing, withholding, and stopping dialysis. This Fast Fact reviews key concepts of the ACP process for CKD patients.
Barriers to ACP in CKD
- Being unaware of a poor prognosis. CKD patients may falsely assume they can be kept alive indefinitely on dialysis; end-of-life issues are commonly avoided until late in the illness.
- Many health professionals believe that ACP may destroy hope and that the focus of care should be on their “life-sustaining therapy”, i.e. dialysis.
- Cognitive dysfunction associated with advanced CKD may prevent the ability for meaningful participation in ACP. Discussions must occur early in the illness while comprehension and decision-making capacity are preserved.
Key Aspects of ACP in CKD (See FF #162 for general ACP recommendations)
- ACP should be initiated prior to the need for dialysis. The importance of early discussions is underscored by the fact that only ~ 60% of nephrologists would consider stopping dialysis for a non-decisional patient with unclear prior wishes.
- Include family in ACP discussions.
- CKD patients are often afraid to talk to their loved ones about their preferences; some patients will choose to prolong their time on dialysis due to family pressure.
- Surrogates must be aware of patient preferences and the values upon which these preferences were based.
- Including family is critical in achieving many of the goals of ACP such as strengthening relationships with and relieving emotional and financial burdens on loved ones.
- Provide detailed information as part of pre-dialysis education.
- All treatment options should be fully reviewed: 1) available dialysis modalities, 2) not starting dialysis and continuing conservative management, 3) a time-limited trial of dialysis, and 4) stopping dialysis with expectation of death. (See below for clinical practice guidelines on not starting or discontinuing dialysis).
- Estimate prognosis. The annual death rate for patients initiating dialysis is 20-25%; 15% – 25% of these deaths result from decisions to withdraw dialysis. Patients with CKD who elect dialysis generally experience progressive functional decline over months to years, punctuated by episodes of life-threatening complications. Elderly or chronically ill patients with co-morbid diseases, at the initiation of dialysis, can be expected to have greater complications and a shorter survival. Poor prognostic factors include older age, low serum albumin, poor functional status, and comorbid illnesses such as diabetes and cardiovascular disease. Anuric patients, who elect to not initiate or discontinue dialysis, typically survive for 7-14 days. The prognosis is longer for patients with residual renal function who continue to make urine.
- Emphasize how you expect their illness and proposed treatments will impact their daily function. Discuss the impact of the various dialysis options on day-to-day function.
Patients Selection for Withholding or the Withdrawal Dialysis (1)
- Patients who, being fully informed and making voluntary choices, decline to begin or request dialysis be stopped.
- Patients who no longer posses decision-making capacity, who have previously indicated refusal of dialysis.
- Patients who do not possess decision-making capacity and whose surrogate declines dialysis or determines it should be discontinued.
- Patients with irreversible, profound neurological impairment such that they lack signs of thought, sensation, purposeful behavior, and awareness of self and environment.
- Patients whose medical conditions precludes the technical process of dialysis.
- Shared Decision-Making in the Appropriate Initiation of and withdrawal from Dialysis. Clinical Practice Guideline. Renal Physicians Association and American Society of Nephrology. Washington DC, 2000
- Chambers EJ, Germain M, and Brown E, eds. Supportive Care for the Renal Patient. Publisher: Oxford University Press; 2004.
- Davison SN. Facilitating Advance Care Planning for Patients with End Stage Renal Disease: the Patient Perspective. CJASN in press 2006
- Holley JL. Palliative Care in End Stage Renal Disease: Focus on Advance Care Planning, Hospice Referral, and Bereavement. Seminars in Dialysis 18(2): 154-156,
- Michel DM, Moss AH. Communicating Prognosis in the Dialysis Consent Process: A Patient-Centered, Guideline-Supported Approach. Advances in CKD. 12 (2): 196-201.
Version History: This Fast Fact was originally edited by David E Weissman MD and published in September 2006. Version copy-edited in April 2009; then again in November 2015.
Fast Facts and Concepts are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual Fast Fact are solely responsible for that Fast Fact’s content. The full set of Fast Facts are available at Palliative Care Network of Wisconsin with contact information, and how to reference Fast Facts.
Copyright: All Fast Facts and Concepts are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (http://creativecommons.org/licenses/by-nc/4.0/). Fast Facts can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a Fast Fact, let us know!
Disclaimer: Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.